Fit-for-purpose matchmaking webinar: a data selection and RWE approach for both regulatory and HTA audiences
June 18, 2024 | RWE, eca, external control arms, real-world evidence, regulatory
This webinar reviews considerations for the design and data selection for RWE studies, including external control arm studies, to meet regulatory and HTA needs.
Regulators and agencies responsible for market authorization and health technology assessment (HTA) are increasingly using real-world evidence (RWE) to enhance their decision-making. Life sciences companies must ensure that data utilized for RWE generation is considered fit-for-purpose.
Focusing on an external control arm (ECA) use case, we will share lessons learned highlighting the advantages of a data-agnostic approach to data selection, understanding regulatory and HTA expectations, and obtaining diverse stakeholder insights. The audience will gain appreciation for considering multiple perspectives, including regulators, HTAs and payers, when evaluating data and planning for RWE submissions.
Of interest to all those interested in: pharmacoepidemiology, RWE, market access, manufacturers, biotech, data vendors.
This content was provided by Genesis Research Group
Company Details
Latest Content from Genesis Research Group
Genesis Research Group’s ISPOR Europe award-winning poster authors interviewed online
Genesis Research Group's poster 'Payer Perspective on the Impact of Real-world Evidence in Health Technology Assessments of Precision Oncology Treatments Across Europe: Results From an Online Survey' was recently named as...
Innovating Differently: A Conversation with David W. Miller, CEO of Genesis Research Group
A recent interview with Dr. David W. Miller, Chairman and CEO of Genesis Research Group, about his vision for the business, the changing face of research, and their unique value proposition...
Genesis Research Group unveils enhanced US market access data analytics
Genesis Research Group (“Genesis”), a pioneer of tech-enabled real-world evidence (RWE), health economics and outcomes research (HEOR), and market access services, announces the expansion of its real-world data analytics capabilities...
Assessing opportunities for manufacturers to communicate the value of therapies to oncology clinical pathway (OCP) developers
Based on insights from 15 U.S. payers and providers, this white paper explores how manufacturers can effectively engage oncology clinical pathway (OCP) developers.
Genesis Research Group Announces Participation of CEO David W. Miller in New ITN Business Healthcare Program
Genesis Research Group, led by newly appointed CEO, David W. Miller, is spotlighted in June’s launch of ITN Business’ “Advancing Healthcare” program for its ‘innovate differently’ approach to supporting life...
Alice Beer of ITN Business recently interviewed David W. Miller, CEO of Genesis Research Group, on ‘Advancing Healthcare’
ITN Business invited Genesis Research Group to contribute to a news style programme 'Advancing Healthcare' featuring key opinion leaders in the healthcare sector. Our CEO David W. Miller was one...
How does Genesis Research Group ‘Innovate differently’?
New Genesis Research Group CEO David W. Miller explains what we mean when we say we help our life science clients to 'Innovate differently' and transform the way they engage...
Envision Analogue – An Introduction
Powered by primary payer market research, Envision is an online platform that provides forward-looking evaluations and comprehensive strategic direction for market access viability after an oncology product has received positive...
World EPA Congress 2024: ‘Shining the light on vaccine market access’ by Genesis Research Group
A presentation with Katrin Nather, PhD, Associate Director, and Tijana Ignjatovic, Executive Director, Genesis Research Group. Contact solutions@genesisrg.com or visit www.genesisrg.com. With more and more innovative vaccines and immunization strategies...
Fit-for-purpose matchmaking webinar: a data selection and RWE approach for both regulatory and HTA audiences
This webinar reviews considerations for the design and data selection for RWE studies, including external control arm studies, to meet regulatory and HTA needs. Regulators and agencies responsible for market...